A retrospective study of ampullary adenocarcinomas: Overall survival and responsiveness to fluoropyrimidinebased chemotherapy

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2349-2353

  Jiang, Z Q ^a   Varadhachary, G ^a   Wang, X ^a   Kopetz, S ^a   Lee, J E ^a   Wang, H ^a   Shroff, R ^a   Katz, M ^a   Wolff, R A ^a   Fleming, J ^a   Overman, M J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ampullary adenocarcinomas; Chemotherapy; Fluoropyrimidine; Gemcitabine; Periampullary

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; PLATINUM COMPLEX;

AMPULLARY ADENOCARCINOMA; AMPULLARY CARCINOMA; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DUODENUM CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; METASTASIS RESECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SURVIVAL TIME; VATER PAPILLA CARCINOMA;

AMPULLARY ADENOCARCINOMAS; CHEMOTHERAPY; FLUOROPYRIMIDINE; GEMCITABINE; PERIAMPULLARY;

ADENOCARCINOMA; AMPULLA OF VATER; ANTIMETABOLITES, ANTINEOPLASTIC; COMMON BILE DUCT NEOPLASMS; DEOXYCYTIDINE; DUODENAL NEOPLASMS; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL; TREATMENT OUTCOME;

EID: 84878900975     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt191     Document Type: Article

References (17)

1. Yeo CJ, Sohn TA, Cameron JL et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998; 227: 821-831.
2. Albores-Saavedra J, Schwartz AM, Batich K et al. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5625 cases from the SEER program. J Surg Oncol 2009; 100: 598-605.
3. Nathan H, Pawlik TM, Wolfgang CL et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007; 11: 1488-1496; discussion 1496-1487.
4. Kimura W, Futakawa N, Yamagata S et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994; 85: 161-166.
5. Kohler I, Jacob D, Budzies J et al. Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol 2011; 135: 202-211.
6. Westgaard A, Tafjord S, Farstad IN et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008; 8: 170.
7. Ruemmele P, Dietmaier W, Terracciano L et al. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol 2009; 33: 691-704.
8. Fischer HP, Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11: 301-309.
9. Zhou H, Schaefer N, WolffM et al. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 2004; 28: 875-882.
10. Roh YH, Kim YH, Lee HW et al. The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology 2007; 54: 1641-1644.
11. Sessa F, Furlan D, Zampatti C et al. Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch 2007; 451: 649-657.
12. Hansel DE, Maitra A, Lin JW et al. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J Clin Oncol 2005; 23: 1811-1818.
13. Santini D, Perrone G, Vincenzi B et al. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol 2008; 19: 724-728.
14. Neoptolemos JP, Moore MJ, Cox TF et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine versus observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308: 147-156.
15. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
16. Gibson MK, Holcroft CA, Kvols LK et al. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005; 10: 132-137.
17. Overman MJ, Varadhachary GR, Kopetz S et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009; 27: 2598-2603.